Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization

Shanghai China, June 28, 2020 – Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced the completion of the C + round financing. The capital raised will be used not only to support the company’s existing pipeline products, but also to support the commercialization of new products. The C+ round of funding was invested by Tigermed, BioTrackCapital, Yingke PE and Huayin Finance & Investment. Together with the previous round C financing led by Yanyuan Capital, the two rounds of financing totaled RMB 390 million.